Annals of Hematology

, Volume 92, Issue 10, pp 1351–1358 | Cite as

Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab

  • Zi-Zhen Xu
  • Zu-Guang Xia
  • Ai-Hua Wang
  • Wen-Fang Wang
  • Zhi-Yin Liu
  • Li-Yun Chen
  • Jun-Min Li
Original Article

Abstract

Diffuse large B cell lymphoma (DLBCL) represents the most common subtype of non-Hodgkin lymphoma and accounts for approximately 30 % of newly diagnosed lymphoid neoplasms in Western countries, and 40–50 % in China. A better understanding of the biology of DLBCL is needed for the development of potential therapeutic agents that target specific intracellular pathways. In this study, expression of the important components of the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway and their clinical significance were investigated in 73 DLBCL cases. The effect of rituximab alone or combined with the PI3K/AKT/mTOR pathway inhibitor rapamycin was further evaluated in the DLBCL cell lines. A total of 73 patients were identified, including 45 men and 28 women aged 18 to 78 years (median age 50 years). Of these patients, p-AKT was positive in 40 cases (54.8 %), p-p70S6K in 34 cases (46.6 %), and p-4E-BP1 in 33 cases (45.2 %). Activation of the PI3K/AKT/mTOR pathway was related to poor disease outcome in DLBCL patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) but not in those treated with rituximab-CHOP. Rituximab combined with rapamycin synergically downregulated the PI3K/AKT/mTOR signaling pathway. Western blot analysis revealed a baseline activation status of the PI3K/AKT/mTOR pathway in DLBCL cell lines, with high levels of p-AKT, p-mTOR, in addition to downstream molecules p-p70S6K and p-4E-BP1. The results indicate that the PI3K/AKT/mTOR pathway is a potentially important signaling route and an unfavorable prognostic factor for DLBCL. Patients with PI3K/AKT/mTOR activation experience a more rapidly deteriorating clinical course with poor treatment response and decreased survival time. Addition of rituximab could downregulate PI3K/AKT/mTOR activation, reversing its negative effect on chemotherapy-treated patients. In addition, our results indicate that the combination of rituximab and inhibition of the activated PI3K/AKT/mTOR pathway could be a promising target for DLBCL therapeutic intervention in the future.

Keywords

PI3K/AKT/mTOR pathway Diffuse large B cell lymphoma Rituximab Rapamycin 

Notes

Acknowledgments

This work was supported in part by the Shanghai Commission of Science and Technology (grants 44107025 and 05DZ19317), the National Natural Science Foundation of China (grants 30570777 and 30750335), the Chinese National High Tech Program (grant 863:2006AA02A301), the Shanghai Commission of Science and Technology (grants 08410708800 and 11140901200), and the Program for Outstanding Young Teachers in Universities of Shanghai (JDY09084).

Conflict of interest

All authors declare that they have no conflict of interest.

References

  1. 1.
    Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) World Health Organization classification of tumors: pathology and genetics of tumors of hematopoetic and lymphoid tissues. IARC, LyonGoogle Scholar
  2. 2.
    Li JM, Wang L, Shen Y et al (2007) Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients. Ann Hematol 86:639–645CrossRefPubMedGoogle Scholar
  3. 3.
    Mey U, Hitz F, Lohri A, Pederiva S, Taverna C, Tzankov A, Meier O, Yeow K, Renner C (2012) Diagnosis and treatment of diffuse large B-cell lymphoma. Swiss Med Wkly 142:0. doi:10.4414/smw.2012.13511
  4. 4.
    Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511CrossRefPubMedGoogle Scholar
  5. 5.
    Rosenwald A, Wright G, Chan WC et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 20:1937–1947CrossRefGoogle Scholar
  6. 6.
    Uddin S, Hussain AR, Siraj AK et al (2006) Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 108:4178–4186CrossRefPubMedGoogle Scholar
  7. 7.
    Wanner K, Hipp S, Oelsner M, Ringshausen I, Bogner C, Peschel C, Decker T (2006) Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 134:475–484CrossRefPubMedGoogle Scholar
  8. 8.
    Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296:1655–1657CrossRefPubMedGoogle Scholar
  9. 9.
    Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, McCubrey JA (2003) Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17:590–603CrossRefPubMedGoogle Scholar
  10. 10.
    Morgensztern D (2005) McLeod HL.PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16:797–803CrossRefPubMedGoogle Scholar
  11. 11.
    Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282CrossRefPubMedGoogle Scholar
  12. 12.
    Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244PubMedGoogle Scholar
  13. 13.
    Friedberg JW (2011) Relapsed/refractory diffuse large B-cell lymphoma. Hematol Am Soc Hematol Educ Program 2011:498–505CrossRefGoogle Scholar
  14. 14.
    Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129:1261–1274CrossRefPubMedGoogle Scholar
  15. 15.
    Fillmore GC, Wang Q, Carey MJ, Kim CH, Elenitoba-Johnson KS, Lim MS (2005) Expression of Akt (protein kinase B) and its isoforms in malignant lymphomas. Leuk Lymphoma 46:1765–1773CrossRefPubMedGoogle Scholar
  16. 16.
    Hasselblom S, Hansson U, Olsson M et al (2010) High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Br J Haematol 149(4):560–568CrossRefPubMedGoogle Scholar
  17. 17.
    Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754–758CrossRefPubMedGoogle Scholar
  18. 18.
    Suzuki E, Umezawa K, Bonavida B (2007) Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene 26:6184–6193CrossRefPubMedGoogle Scholar
  19. 19.
    Ansell SM, Tang H, Kurtin PJ et al (2011) Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 12(4):361–368CrossRefPubMedGoogle Scholar
  20. 20.
    Fingar DC, Blenis J (2004) Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23:3151–3171CrossRefPubMedGoogle Scholar
  21. 21.
    Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, Sawyers CL, Lichtenstein AK (2004) AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 279:2737–2746CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Zi-Zhen Xu
    • 1
    • 3
  • Zu-Guang Xia
    • 2
  • Ai-Hua Wang
    • 3
  • Wen-Fang Wang
    • 3
  • Zhi-Yin Liu
    • 3
  • Li-Yun Chen
    • 3
  • Jun-Min Li
    • 3
  1. 1.Department of Laboratory Medicine, Shanghai Rui Jin HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
  2. 2.Department of Medical OncologyFudan University Shanghai Cancer CenterShanghaiChina
  3. 3.Department of Hematology, Shanghai Institute of Hematology, Shanghai Rui Jin HospitalShanghai Jiao Tong University School of MedicineShanghaiChina

Personalised recommendations